Guardant Health, Inc. (GH)

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health (Nasdaq: GH), a leading precision oncology company, and Trial Library, an AI technology company enabling oncology clinical trials as a care option, today announced a strategic collaboration to increase access to cancer clinical trials in the United States. The collaboration combines Guardant Health's suite of cutting-edge precision oncology diagnostics with Trial Library's AI-powered matching and patient navigation platform. Together, the comp.

PALO ALTO, Calif. & ROME--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking.

Federated Hermes Inc. lifted its stake in shares of Guardant Health, Inc. (NASDAQ: GH) by 72.4% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,465,438 shares of the company's stock after purchasing an additional 615,429 shares during the quarter. Federated Hermes

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025. Oral presentations will highlight results generated with Guardant Reveal, the company's tissue-free test for detecting minimal residual disease (MRD.

Here is how Guardant Health (GH) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

Shares of Guardant Health, Inc. (NASDAQ: GH - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty-four brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and twenty-three have assigned a buy recommendation to the company. The average 1-year

Turkey isn't the only thing making investors tired this Thanksgiving: AI fatigue is setting in as bubble fears rise and tech trades at dot-com era multiples. Record AI spending continues despite skepticism over near-term payoffs and many firms reporting zero measurable returns. AI investment could reach $4 trillion by 2030, while tech leaders acknowledge the risk of irrational spending and the potential for a bubble to burst.

Creative Planning grew its position in shares of Guardant Health, Inc. (NASDAQ: GH) by 26.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,172 shares of the company's stock after acquiring an additional 11,449 shares during

Gamehost Inc. (TSE: GH - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of C$11.69 and traded as low as C$11.65. Gamehost shares last traded at C$11.70, with a volume of 11,000 shares. Gamehost Stock Up 0.1% The firm's fifty day simple

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the public launch of the Single Namespace Working Group (SNS), a 34-member, cross-industry consortium which has drafted the first open standard for exabyte-scale data interoperability. Managing exabyte-scale data across different storage providers is often disruptive, time-consuming, and ultimately costly due to progressively larger data sets needing faster solutions. SN.

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its Guardant Reveal® blood test to include late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal tracks more than 20,000 epigenomic (methylation) signals to measure changes in circulating tumor DNA (ctDNA) levels in a patient's blood to predict outcomes sooner than imaging without the need for a tissue sample. Building on.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UK Fireside chat on Wednesday, November 19 at 9:30 a.m. Greenwich Mean Time Piper Sandler 37th Annual Healthcare Conference in New York, NY Fireside chat on Tuesday, December 2 at 8:30 a.m. Eastern Time Interested parties may access live and archived.

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 21, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 184,961 shares of its common stock to 272 new non-executive employees and one non-qualified stock option award to purchase 5,731 shares of its common stock to one new non-executive employee with a grant date of Octobe.

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating that its Guardant Reveal® blood test helps clinicians to assess the effectiveness of chemotherapy in patients with advanced solid tumors months earlier than conventional methods. This is the first robust clinical validation study of pan-cancer chemotherapy monitoring, published in the Journal of Liquid Biopsy. The study used a tissue-free, methylat.

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in screening for colorectal cancer (CRC). Shield is the first and only blood test to receive FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. In the analysi.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million aggregate principal amount of 0% convertible senior notes due 2033 (the “notes”) in a private offering (the “convertible notes offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Th.